Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Dr Reddy's Laboratories (NYSE:RDY) and raises the price target from $67 to $70.
June 01, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Dr Reddy's Laboratories and raises the price target from $67 to $70.
The news of Barclays maintaining an Overweight rating on Dr Reddy's Laboratories and raising the price target from $67 to $70 indicates a positive outlook for the stock. This could lead to an increase in investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100